Cardiovascular Disease Risk Assessment
Customize your policy alerts
Sign up for Molina Healthcare Policy G2050 alerts
Get alerted when Policy G2050 changes without checking for updates manually.
Monitor payer policy activity
Defines Molina Healthcare's coverage policy for laboratory and biomarker testing used to assess cardiovascular disease (CVD) risk for adults, including which tests meet or do not meet coverage criteria and recommended frequencies.
CC3 edited to clarify that Lp(a) screening is once per lifetime and should occur when the individual is 18 years of age or older, and now meets coverage criteria.
CC4 edited to require two hs-CRP measurements (initial and confirmatory at least two weeks later) with annual measurement thereafter if elevated.
CC5 edited to define that hs-CRP and conventional CRP have distinct coverage stances; hs-CRP limited as described and conventional CRP does not meet coverage criteria for CVD risk assessment.
CPT code 0541U was added via an off-cycle coding modification (effective 4/1/2025).
Updated laboratory name and description for CPT code 0308U (and 0309U mentioned) with effective date 4/1/2025.
Coverage criteria and guideline context
Coverage criteria and exclusions
Covered when ALL of the following criteria and specified indications are met:
ALL of the following
ONE OF
- Screening for cardiovascular disease: every 4 years for individuals ages 18-79.ages 18-79
- Annual screening for individuals at increased CVD risk as defined by 2013 ACC/AHA PCEs (estimate 10-year risk).
- Annual testing for individuals at increased risk of dyslipidemia due to conditions including obesity/metabolic syndrome, nephrotic syndrome, hypothyroidism or hyperthyroidism, pancreatitis, diabetes, chronic kidney disease, Cushing syndrome, pregnancy, cholestatic liver disease, or lipid metabolism disorders.
- For individuals initiating or receiving statin therapy: baseline measurement before initiation; every 4–12 weeks after initiation or change of therapy; annually when stable with no medication changes.
- Annual lipid panel for individuals on long-term drug therapy that requires lipid monitoring (e.g., isotretinoin, antipsychotics).
- For HIV-positive individuals starting or on antiretroviral therapy (ART): baseline before initiation; every 1–3 months after initiation/change; every 6–12 months when stable.
ALL of the following
- Measured once per lifetime; measurement should occur when the individual is 18 years of age or older.Once per lifetime, age ≥18
ALL of the following
- One test for initial screening.
- If initial screen is abnormal, perform a confirmatory hs‑CRP no sooner than two weeks after the initial test.≥2 weeks
- If two measurements confirm elevated hs‑CRP, annual measurement thereafter is allowed.
Evidence and guideline context
Context from major guideline documents and evidence summaries relevant to biomarker utility and interpretation:
Coverage-related guidance and guideline-derived criteria
Guideline-derived positions and advisory statements that inform appropriate test selection and frequency (informational — reflect guideline advice rather than payer authorization rules):
Coverage-related recommendations
Summary of coverage‑relevant recommendations from major organizations that inform testing cadence and selective use of additional assessments:
Coverage-relevant guideline criteria
Guideline-based intervals and selective use of adjunct tests for refining CVD risk:
Evidence and Guidelines Cited
Key references and guideline documents cited as evidence for policy elements (selected list):
CC3-CC5 coverage criteria
Material revisions to specific coverage criteria (CC3–CC5) implemented in the policy update:
Applicable codes, thresholds, and coding updates
| No codes listed |
| No codes listed |
| Examples of commercial cardiovascular risk panels (e.g., Genova Cardio Check; Cleveland HeartLab profiles) |
| No codes listed |
| CMS/NCD reference for lipid testing (link to CMS coverage database) |
Ordering, monitoring, and administrative considerations
Apply coverage criteria and follow specified screening intervals
Ordering clinicians must apply Molina Healthcare coverage criteria based on the individual's benefits and follow the specified screening intervals: lipid panel every 4 years for ages 18–79 and annually for individuals at increased CVD risk; annual testing for persons with conditions that increase dyslipidemia risk; baseline and follow-up intervals around statin or ART initiation as specified in policy.
- Lipid panel to screen: every 4 years for ages 18–79; annually if increased risk per 2013 ACC/AHA PCEs.
- Annual lipid testing for conditions increasing dyslipidemia (eg, diabetes, CKD, thyroid disorders, pregnancy, nephrotic syndrome, pancreatitis, lipid metabolism disorders).
- For statin therapy: baseline before initiation; every 4–12 weeks after start/change; annually if stable.
- For ART in HIV: baseline before initiation; every 1–3 months after start/change; every 6–12 months if stable.
Administrative note — no prior authorization or step-therapy specified
The policy text in the referenced sections does not impose prior authorization, special documentation, denial-risk statements, billing rules, or step-therapy requirements for these items.
Proprietary cardiovascular risk panels have unclear clinical utility
The policy states that commercially available cardiovascular risk panels lack demonstrated clinical utility and the impact of these panels on patient management is unknown.
- Examples listed include Genova Cardio Check™ and Cleveland HeartLab profiles, but these panels are noted as having unclear clinical utility.
Monitoring frequency guidance per CMS for long‑term lipid therapy
When monitoring long-term anti-lipid dietary or pharmacologic therapy, CMS guidance referenced in the policy indicates that an annual lipid panel is reasonable; more frequent testing (up to six times in the first year) may be medically necessary for monitoring therapy, and LDL or total cholesterol may be measured three times yearly after goals are achieved.
- Annual lipid panel is usually adequate for long-term monitoring.
- Any single component or measured LDL may be medically necessary up to six times in the first year for therapy monitoring.
- LDL or total cholesterol may be measured three times yearly after treatment goals are achieved.
Defer to applicable government (Medicare/Medicaid) policies when conflicting
If there is a conflict between this Molina Healthcare Policy and applicable government policy (for example, Medicare LCDs/NCDs or state Medicaid rules), the government policy governs; providers should consult CMS or state Medicaid sites for up-to-date coverage determinations.
- Government (Medicare/Medicaid) policy takes precedence over this Policy in case of conflict.
- Providers should check the CMS Medicare Coverage Database and applicable state Medicaid websites for current rules.
References — informational only; no authorization actions specified
The References section lists the scientific citations supporting the policy; those reference entries do not specify prior authorization, denial-risk actions, documentation requirements, billing rules, or step-therapy steps.
- References include guideline and peer-reviewed citations (items numbered in the policy) used to support clinical statements.
Coding updates and laboratory identifiers (off‑cycle changes)
The policy includes off-cycle laboratory coding modifications: CPT code 0541U was added (effective 4/1/2025) and laboratory name/description updates were made for CPT code 0308U (and references to 0309U); these coding updates are noted in the revision history.
Definitions and test descriptions
Evidence, guidelines, and referenced studies
Evidence and Guidelines Cited
Detailed bibliographic listing and guideline sources underpinning the policy (reference index provided in policy):
Evidence and guideline context
Background context and guideline summaries (duplicate placement for background):
Coverage-relevant recommendations (background rationale)
Additional background rationale from organizations informing selective test use and frequency:
Policy changes and updates
Policy G2050 revised: updated coverage criteria CC3–CC5 to clarify Lp(a) lifetime screening age, require confirmatory and follow-up cadence for hs-CRP, and define coverage distinctions for hs-CRP versus conventional CRP; includes multiple coverage criteria edits for biomarker testing.
Off-cycle coding modification added CPT code 0541U and updated laboratory name/description for CPT code 0308U (references to 0309U updated), effective April 1, 2025.
CC3–CC5 edits — Lp(a) once per lifetime; hs‑CRP confirmation and annual cadence
Coverage criteria CC3–CC5 were edited to clarify Lp(a) and hs‑CRP testing cadence and frequency: Lp(a) is permitted once per lifetime at age ≥18; hs‑CRP requires an initial test and confirmatory test at least two weeks later, with annual testing thereafter if confirmed elevated.
- CC3: Lp(a) measurement once per lifetime when individual is 18 years or older.
- CC4: hs‑CRP testing requires initial test; if abnormal, confirmatory test no sooner than two weeks later; annual measurement if elevated is confirmed.
- CC5: Clarified that hs‑CRP is limited as described and conventional CRP does not meet coverage criteria for CVD risk assessment.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.